Literature DB >> 16536798

Protein kinase D distribution in normal human epidermis, basal cell carcinoma and psoriasis.

V L Ristich1, P H Bowman, M E Dodd, W B Bollag.   

Abstract

BACKGROUND: Keratinocytes undergo a defined programme of proliferation and differentiation during normal stratification of the epidermis. Anomalies in the signalling pathways controlling this process probably contribute to the pathogenesis of hyperproliferative dermatological diseases, including psoriasis and basal cell carcinoma (BCC). We have previously proposed that protein kinase D (PKD) is a proproliferative signalling enzyme in keratinocytes and have speculated that abnormalities in its levels or regulation may contribute to hyperproliferative disorders of the skin.
OBJECTIVES: To determine if hyperproliferative human skin disorders are characterized by abnormal protein expression or distribution of PKD, normal human epidermis was compared with BCC and uninvolved and involved psoriatic epidermis.
METHODS: To examine protein expression, immunohistochemical analysis of human samples and Western blotting of neoplastic mouse keratinocytes was performed. Western analysis of neoplastic mouse cells using a phosphospecific PKD antibody allowed estimation of PKD activation status.
RESULTS: Normal human epidermis demonstrated predominant PKD protein expression in the stratum basalis, the proliferative epidermal compartment, with decreased relative expression throughout the suprabasal strata. Uninvolved psoriatic skin showed a similar pattern, but in contrast, psoriatic lesions demonstrated a diffuse distribution of PKD staining throughout all strata. The majority of BCCs examined showed significant PKD protein levels and, in those biopsies in which the levels could be compared, elevated PKD levels relative to normal epidermis. PKD levels and activation status were also increased in a neoplastic mouse keratinocyte cell line.
CONCLUSIONS: PKD was elevated or misdistributed in the hyperproliferative human skin disorders, BCC and psoriasis, as well as neoplastic mouse keratinocytes. We speculate that PKD exerts proproliferative and/or antidifferentiative effects in the epidermis, and that anomalous distribution and/or activation of PKD may be involved in precipitating or sustaining the disease process in BCC and psoriasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16536798     DOI: 10.1111/j.1365-2133.2005.07073.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  19 in total

Review 1.  Protein kinase D as a potential new target for cancer therapy.

Authors:  Courtney R LaValle; Kara M George; Elizabeth R Sharlow; John S Lazo; Peter Wipf; Q Jane Wang
Journal:  Biochim Biophys Acta       Date:  2010-05-24

2.  Diagnosis of basal cell carcinoma by infrared spectroscopy of whole blood samples applying soft independent modeling class analogy.

Authors:  Mohammadreza Khanmohammadi; Razieh Nasiri; Keyvan Ghasemi; Simin Samani; Amir Bagheri Garmarudi
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-02       Impact factor: 4.553

3.  Protein kinase D2 is a novel regulator of glioblastoma growth and tumor formation.

Authors:  Ninel Azoitei; Alexander Kleger; Nina Schoo; Dietmar Rudolf Thal; Cornelia Brunner; Ganesh Varma Pusapati; Alina Filatova; Felicitas Genze; Peter Möller; Til Acker; Rainer Kuefer; Johan Van Lint; Heinrich Baust; Guido Adler; Thomas Seufferlein
Journal:  Neuro Oncol       Date:  2011-07       Impact factor: 12.300

4.  Protein kinase D1 deficiency promotes differentiation in epidermal keratinocytes.

Authors:  Vivek Choudhary; Lawrence O Olala; Ismail Kaddour-Djebbar; Inas Helwa; Wendy B Bollag
Journal:  J Dermatol Sci       Date:  2014-10-02       Impact factor: 4.563

Review 5.  Emerging roles of protein kinase D1 in cancer.

Authors:  Vasudha Sundram; Subhash C Chauhan; Meena Jaggi
Journal:  Mol Cancer Res       Date:  2011-06-16       Impact factor: 5.852

6.  The potential use of protein kinase D inhibitors for prevention/treatment of epidermal tumors.

Authors:  Senthil Nathan Arun; Ding Xie; M Ernest Dodd; Xiaofeng Zhong; Wendy B Bollag
Journal:  J Dermatol Sci       Date:  2010-08-10       Impact factor: 4.563

7.  Ultraviolet activation of PKD: implications for skin cancer.

Authors:  Wendy B Bollag; Roni J Bollag
Journal:  Future Oncol       Date:  2011-04       Impact factor: 3.404

Review 8.  Functional and therapeutic significance of protein kinase D enzymes in invasive breast cancer.

Authors:  Nisha Durand; Sahra Borges; Peter Storz
Journal:  Cell Mol Life Sci       Date:  2015-08-08       Impact factor: 9.261

9.  In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts.

Authors:  Jianxia Guo; Dana M Clausen; Jan H Beumer; Robert A Parise; Merrill J Egorin; Karla Bravo-Altamirano; Peter Wipf; Elizabeth R Sharlow; Qiming Jane Wang; Julie L Eiseman
Journal:  Cancer Chemother Pharmacol       Date:  2012-10-30       Impact factor: 3.333

10.  Protein kinase D1 (PKD1) influences androgen receptor (AR) function in prostate cancer cells.

Authors:  Paul Mak; Meena Jaggi; Viqar Syed; Subhash C Chauhan; Sazzad Hassan; Helal Biswas; K C Balaji
Journal:  Biochem Biophys Res Commun       Date:  2008-07-03       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.